Wire · opportunities
Promising Results for mRNA Cancer Vaccine from Moderna and Merck
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 August 2026 · Fusion42 review
Moderna and Merck report that combining their mRNA-based vaccine intismeran with Merck's immunotherapy Keytruda significantly improves survival and reduces cancer recurrence in melanoma patients compared to Keytruda alone. This Phase 3 trial represents a breakthrough in personalised cancer treatment using mRNA technology.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have new proof mRNA tech can improve cancer survival when combined with immunotherapy. Expect trials expanding to other tumour types to open treatment doors and increase demand for personalised vaccine platforms.
◆ Coverage
1 source · 19 Aug 2026
◆ Related on Wire
◆ Topics